Supriya Lifescience Releases Q4 FY26 Earnings Call Transcript, Highlights USFDA Approval
Supriya Lifescience reported FY26 revenue of ₹828 crores (up 18.9% YoY) and EBITDA of ₹294 crores (35.5% margin). Q4 FY26 revenue was ₹277 crores (up 50% YoY). The company received USFDA EIR with VAI classification for its Lote facility. It reiterated FY27 revenue guidance of ₹1,000 crores and EBITDA margin of 33-35%. Patalganga facility Phase 1 capex is ₹200 crores.
The announcement includes strong financial performance, a significant regulatory approval (USFDA EIR), and clear future growth guidance and expansion plans, all of which are material factors for investors.
The company reported strong financial results with significant year-on-year growth in revenue and EBITDA, met its revenue targets, and achieved a key regulatory milestone (USFDA EIR with VAI classification). The outlook for FY27 remains positive with a clear revenue target and ongoing capacity expansion plans.
Supriya Lifescience Limited has released the transcript of its earnings call held on May 28, 2026, discussing the audited financial results for the quarter and year ended March 31, 2026. The company announced a significant regulatory milestone: its Lote facility received the USFDA's Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification following an inspection in February 2026. This inspection resulted in only one minor observation, which was addressed proactively.
For the full year FY26, Supriya Lifescience achieved its revenue target, reporting a revenue of ₹828 crores, a year-on-year growth of 18.9%, in line with the guided growth of approximately 20%. EBITDA stood at ₹294 crores with a margin of 35.5%. The export segment contributed 82% to the revenues, with Europe accounting for 40%. The company also progressed with its backward integration initiatives, reaching 76% in FY26.
In Q4 FY26, revenue from operations was ₹277 crores, a 50% year-on-year growth. EBITDA for the quarter was ₹98 crores, a 44% increase year-on-year, with an EBITDA margin of 35.5%. Profit After Tax (PAT) stood at ₹74 crores, with a PAT margin of 26.8%.
During FY26, the company introduced a new cardiovascular product in Q3 FY26, which began contributing in Q4 FY26, and an ADHD product with strong demand in LATAM and Europe. A liquid anesthetic product was also commercialized. The company plans to strengthen its anesthetic and ADHD portfolios in FY27 with approximately two new launches in each segment.
The company reiterated its guidance of approximately 20% annual revenue growth and an EBITDA margin of 33% to 35% for FY27, with a trajectory to achieve ₹1,000 crores in revenue by FY27. Phased development of the Patalganga land will begin with Phase 1 groundbreaking in FY27, with an estimated capex of ₹200 crores for Phase 1.
Capex for FY26 was ₹152 crores, primarily for the Ambernath facility. For FY27, the company plans to allocate significant funds towards capacity building, including ₹200 crores for Phase 1 of the Patalganga facility over the next two years. The company is also focusing on CMO/CDMO opportunities.
Regarding specific products, the cardiovascular intermediate is scaling up well, with significant revenue contribution expected in FY27. The company is not participating in any PLI schemes and focuses on customer qualification. The anesthetic portfolio has a capacity of over 1,000 metric tons, with CMO discussions in advanced stages. The F block at the Lote Parshuram plant will add 150 to 200 KL capacity with an estimated capex of ₹40-50 crores over two years. The DSM contract contributed ₹30-35 crores in FY26, with a peak expectation of ₹60 crores in FY27. Ambernath facility's full revenue contribution is expected in 2-3 years, with initial revenue generation starting in FY27, mainly from semi-regulated markets. The contrast media product is now expected to launch in H2 FY27. The company is not seeing significant pricing pressure due to its agile working model and ability to pass on cost increases.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.